GSK to manufacture 60 million doses of Novavax vaccine for the UK
Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021
GlaxoSmithKline has agreed in principle to support Novavax in the production of up to 60 million doses of its COVID-19 vaccine candidate, NVX-CoV2373, for use in the UK by providing fill and finish manufacturing capacity at its Barnard Castle facility in England.
Fill and finish is the completion stage of vaccine manufacturing, which involves preparing vials of the final vaccine and packaging them for distribution and use. Operations could start as early as May 2021.
GSK is now preparing the Barnard Castle site in the north east of England, including a rapid technology transfer with Novavax. The site is a specialised facility that produces GSK pharmaceutical and vaccine products.
GSK said it intends to manufacture most, if not all, of the 60 million vaccine doses the UK Government has secured under an advance purchase agreement with Novavax.
"We have ensured that we can deliver these volumes without impacting supply of our other vital medicines and vaccines, and without disruption to the other COVID-19 collaborations GSK is engaged in globally," said Roger Connor, President, GSK vaccines.
The protein antigen component of NVX-CoV2373 is also produced in the north east of England by Novavax' manufacturing partner, Fujifilm Diosynth Biotechnologies, at its site in Billingham, Stockton-on-Tees.
The Novavax vaccine candidate has demonstrated strong potential efficacy in Phase III clinical trials, including against the B.1.1.7 variant circulating in the UK. Submission of the vaccine for review by regulatory authorities in the UK is expected during the second quarter.
In a statement, UK Prime Minister Boris Johnson said GSK's investment showed the "strength of UK manufacturing" and would help with the nation's vaccine rollout, including the targets of offering a first jab to all over 50s by 15 April and all adults by the end of July.
GSK is collaborating with several organisations around the world on COVID-19 vaccines by providing access to its adjuvant technology. The use of an adjuvant can be of particular importance in a pandemic as it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance